Published in J Urol on May 29, 2013
Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA (2015) 9.02
Magnetic resonance imaging-ultrasound fusion biopsy for prediction of final prostate pathology. J Urol (2014) 1.33
Current status of magnetic resonance imaging (MRI) and ultrasonography fusion software platforms for guidance of prostate biopsies. BJU Int (2014) 1.18
Prostate Cancer: Interobserver Agreement and Accuracy with the Revised Prostate Imaging Reporting and Data System at Multiparametric MR Imaging. Radiology (2015) 1.16
Multiparametric MRI in the PSA screening era. Biomed Res Int (2014) 0.91
Multiparametric MRI in biopsy guidance for prostate cancer: fusion-guided. Biomed Res Int (2014) 0.90
Multiparametric magnetic resonance imaging and image-guided biopsy to detect seminal vesicle invasion by prostate cancer. J Endourol (2014) 0.89
Natural history of small index lesions suspicious for prostate cancer on multiparametric MRI: recommendations for interval imaging follow-up. Diagn Interv Radiol (2014) 0.89
Focal laser ablation for localized prostate cancer: principles, clinical trials, and our initial experience. Rev Urol (2014) 0.87
Prostate diffusion imaging with distortion correction. Magn Reson Imaging (2015) 0.83
Prostate cancer diagnosis: the feasibility of needle-based optical coherence tomography. J Med Imaging (Bellingham) (2015) 0.82
Multiparametric magnetic resonance imaging of the prostate aids detect lesion progression. J Comput Assist Tomogr (2014) 0.82
Image-guided focal therapy for prostate cancer. Diagn Interv Radiol (2014) 0.82
Imaging and pathology findings after an initial negative MRI-US fusion-guided and 12-core extended sextant prostate biopsy session. Diagn Interv Radiol (2014) 0.79
Prostate Radiotherapy in the Era of Advanced Imaging and Precision Medicine. Prostate Cancer (2016) 0.78
Random biopsy: when, how many and where to take the cores? World J Urol (2014) 0.78
Dynamic contrast-enhanced magnetic resonance imaging in prostate cancer clinical trials: potential roles and possible pitfalls. Transl Oncol (2014) 0.78
Preoperative Multiparametric Magnetic Resonance Imaging Predicts Biochemical Recurrence in Prostate Cancer after Radical Prostatectomy. PLoS One (2016) 0.78
Risk stratification of prostate cancer: integrating multiparametric MRI, nomograms and biomarkers. Future Oncol (2016) 0.78
Magnetic Resonance Image-Guided Focal Prostate Ablation. Semin Intervent Radiol (2016) 0.77
Prostate cancer: aggressiveness--MRI can tell. Nat Rev Urol (2013) 0.77
Evaluation of Multiparametric Magnetic Resonance Imaging in Detection and Prediction of Prostate Cancer. PLoS One (2015) 0.77
Will Multi-Parametric Magnetic Resonance Imaging be the Future Tool to Detect Clinically Significant Prostate Cancer? Front Oncol (2014) 0.77
Nonvisible tumors on multiparametric magnetic resonance imaging does not predict low-risk prostate cancer. Prostate Int (2015) 0.77
The prostate cancer prevention trial risk calculator 2.0 performs equally for standard biopsy and MRI/US fusion-guided biopsy. Prostate Cancer Prostatic Dis (2017) 0.75
Assessment of the Performance of Magnetic Resonance Imaging/Ultrasound Fusion Guided Prostate Biopsy against a Combined Targeted Plus Systematic Biopsy Approach Using 24-Core Transperineal Template Saturation Mapping Prostate Biopsy. Prostate Cancer (2016) 0.75
When and how should magnetic resonance imaging be used in evaluation of the patient with prostate cancer or increased prostate specific antigen? J Urol (2013) 0.75
Diagnostic value and relative weight of sequence-specific magnetic resonance features in characterizing clinically significant prostate cancers. PLoS One (2017) 0.75
Prostatic intraepithelial neoplasia-like ductal prostatic adenocarcinoma: A case suitable for active surveillance? Urol Ann (2017) 0.75
Prostate biopsy for the interventional radiologist. J Vasc Interv Radiol (2014) 0.75
The University College London/Medical Research Council/National Institute of Health Research-Health Technology Assessment PROMIS Trial: An Update. Eur Urol Focus (2015) 0.75
Effect of Prostate Magnetic Resonance Imaging/Ultrasound Fusion-guided Biopsy on Radiation Treatment Recommendations. Int J Radiat Oncol Biol Phys (2016) 0.75
Comparison of Multiparametric and Biparametric MRI in First Round Cognitive Targeted Prostate Biopsy in Patients with PSA Levels under 10 ng/mL. Yonsei Med J (2017) 0.75
Current Ability of Multiparametric Prostate Magnetic Resonance Imaging and Targeted Biopsy to Improve the Detection of Prostate Cancer. Urol Pract (2014) 0.75
Functional magnetic resonance imaging and molecular pathology at the crossroad of the management of early prostate cancer. World J Urol (2015) 0.75
Cost-effectiveness of MR Imaging-guided Strategies for Detection of Prostate Cancer in Biopsy-Naive Men. Radiology (2017) 0.75
DNA repair deregulation in discrete prostate cancer lesions identified on multi-parametric MRI and targeted by MRI/ultrasound fusion-guided biopsy. Oncotarget (2017) 0.75
Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol (2007) 9.67
Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia (2009) 7.44
Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med (2015) 6.28
Germline HABP2 Mutation Causing Familial Nonmedullary Thyroid Cancer. N Engl J Med (2015) 5.66
Imaging of angiogenesis: from microscope to clinic. Nat Med (2003) 5.51
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
Rapid cancer detection by topically spraying a γ-glutamyltranspeptidase-activated fluorescent probe. Sci Transl Med (2011) 4.72
Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol (2013) 4.64
Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine (Lond) (2008) 4.08
Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med (2007) 3.88
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol (2003) 3.38
New strategies for fluorescent probe design in medical diagnostic imaging. Chem Rev (2010) 3.35
Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol (2013) 3.34
Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol (2008) 3.30
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther (2010) 3.29
Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. Am J Hum Genet (2005) 3.26
Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes. Nat Med (2008) 3.15
Prostate cancer: value of multiparametric MR imaging at 3 T for detection--histopathologic correlation. Radiology (2010) 3.12
Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dubé syndrome. Cancer Epidemiol Biomarkers Prev (2002) 3.12
Robotic partial nephrectomy for complex renal tumors: surgical technique. Eur Urol (2007) 3.07
Renal tumors in the Birt-Hogg-Dubé syndrome. Am J Surg Pathol (2002) 3.06
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Can magnetic resonance-ultrasound fusion biopsy improve cancer detection in enlarged prostates? J Urol (2013) 2.81
Imaging prostate cancer: a multidisciplinary perspective. Radiology (2007) 2.79
Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med (2011) 2.76
Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet (2012) 2.71
Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci U S A (2007) 2.71
High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors. J Natl Cancer Inst (2005) 2.70
Navigation with electromagnetic tracking for interventional radiology procedures: a feasibility study. J Vasc Interv Radiol (2005) 2.67
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol (2012) 2.61
Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer. J Natl Cancer Inst (2005) 2.60
Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management. AJR Am J Roentgenol (2012) 2.59
Correlation of magnetic resonance imaging tumor volume with histopathology. J Urol (2012) 2.55
Image-guided tumor ablation: proposal for standardization of terms and reporting criteria. Radiology (2003) 2.53
In vivo molecular imaging of cancer with a quenching near-infrared fluorescent probe using conjugates of monoclonal antibodies and indocyanine green. Cancer Res (2009) 2.51
Simultaneous multicolor imaging of five different lymphatic basins using quantum dots. Nano Lett (2007) 2.46
LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol Cancer Ther (2009) 2.43
11C-Acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation. J Nucl Med (2012) 2.42
Real-time MRI-TRUS fusion for guidance of targeted prostate biopsies. Comput Aided Surg (2008) 2.39
Evaluation of non-formalin tissue fixation for molecular profiling studies. Am J Pathol (2002) 2.38
Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? Radiology (2010) 2.38
Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance? Radiology (2013) 2.35
Characteristics of congenital hepatic fibrosis in a large cohort of patients with autosomal recessive polycystic kidney disease. Gastroenterology (2012) 2.33
Evaluation and management of renal tumors in the Birt-Hogg-Dubé syndrome. J Urol (2005) 2.33
The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J Urol (2004) 2.32
Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol (2009) 2.29
Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. Proc Natl Acad Sci U S A (2009) 2.28
Multiparametric magnetic resonance imaging outperforms the Prostate Cancer Prevention Trial risk calculator in predicting clinically significant prostate cancer. Cancer (2014) 2.27
Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood (2004) 2.27
Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst (2008) 2.24
A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res (2011) 2.24
Toxicity of organic fluorophores used in molecular imaging: literature review. Mol Imaging (2009) 2.21
Overall survival advantage with partial nephrectomy: a bias of observational data? Cancer (2013) 2.21
MRI of tumor angiogenesis. J Magn Reson Imaging (2007) 2.19